Search
LB-100
go.drugbank.com/drugs/DB15412InvestigationalLB-100 is under investigation in clinical trial NCT03886662 (A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)).
Anivamersen
go.drugbank.com/drugs/DB16089InvestigationalAnivamersen is under investigation in clinical trial NCT01848106 (A Study to Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI).
CXD101
go.drugbank.com/drugs/DB16182InvestigationalCXD101 is under investigation in clinical trial NCT03873025 (A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-cell Lymphoma).
Synonyms: Hdac-in-4Itepekimab
go.drugbank.com/drugs/DB16206InvestigationalItepekimab is under investigation in clinical trial NCT03546907 (Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-il-33 Mab) in Patients With Moderate-to-severe
ABBV-514
go.drugbank.com/drugs/DB17586InvestigationalABBV-514 is in development for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) as a single agent and in combination with a PD-1 inhibitor.[L45464]
Maridebart Cafraglutide
go.drugbank.com/drugs/DB19339InvestigationalMaridebart Cafraglutide is under investigation in clinical trial NCT05669599 (Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity
Ad-CEA vaccine
go.drugbank.com/drugs/DB17581InvestigationalAd-CEA vaccine is under investigation in clinical trial NCT03050814 (Standard of Care Alone or in Combination With Ad-cea Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal
VIR-5818
go.drugbank.com/drugs/DB28582InvestigationalVIR-5818 is under investigation in clinical trial NCT05356741 (To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants
Pimicotinib
go.drugbank.com/drugs/DB18972InvestigationalIt was initially developed by Abbisko Therapeutics Co in collaboration with Merck KGaA. [L53748] Pimicotinib was granted Fast Track Designation in December 2023 by the FDA. [L53753] … Pimicotinib is under investigation in clinical trial NCT05804045 (Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)).
Synonyms: 1-Pyrrolidinecarboxamide, 3,3-dimethyl-N-[6-methyl-5-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]-2-pyridinyl]-2-oxo-, 3,3-Dimethyl-N-[6-methyl-5-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]-2-pyridinyl]-2-oxo-1-pyrrolidinecarboxamideVevorisertib
go.drugbank.com/drugs/DB21481InvestigationalVevorisertib is under investigation in clinical trial NCT02761694 (Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations … The usage of the INN stem '-sertib' in the name indicates that Vevorisertib is a serine/threonine kinase inhibitor.